133 related articles for article (PubMed ID: 1697152)
1. [Tumoricidal biological response modifiers (BRM)].
Niitsu Y; Kohgo Y; Watanabe N
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152
[TBL] [Abstract][Full Text] [Related]
2. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia.
Fuggetta MP; D'Onofrio C; Bonmassar E
Ann Ist Super Sanita; 1990; 26(3-4):385-95. PubMed ID: 1708953
[TBL] [Abstract][Full Text] [Related]
3. [Bases on timing of combined modality of chemotherapy and immunotherapy].
Ogura T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1414-20. PubMed ID: 1697153
[TBL] [Abstract][Full Text] [Related]
4. [Receptor-mediated cancer therapy--tumoricidal cytokines, adoptive therapy of LAK, TIL].
Niitsu Y; Watanabe N; Kondo H; Kanisawa Y
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1134-41. PubMed ID: 1693487
[TBL] [Abstract][Full Text] [Related]
5. [Therapy by biological response modifiers].
Urushizaki I
Rinsho Ketsueki; 1989 Aug; 30(8):1230-2. PubMed ID: 2689681
[TBL] [Abstract][Full Text] [Related]
6. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
[TBL] [Abstract][Full Text] [Related]
8. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
9. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
10. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
12. [Combination of chemotherapy and immunotherapy in man--review].
Ohnuma T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154
[TBL] [Abstract][Full Text] [Related]
13. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
14. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
15. [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients].
Urushizaki I
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2119-29. PubMed ID: 1699499
[TBL] [Abstract][Full Text] [Related]
16. IL-2/LAK cell treatment for advanced cancers with emphasis on a novel administration.
Auber ML; DeHaven JI; Raich PC; Rogers JS; Crowell EB; Romero P; Mahin EJ; Sosnowski JT; Lamm DL
W V Med J; 1991 Aug; 87(8):344-6. PubMed ID: 1949753
[TBL] [Abstract][Full Text] [Related]
17. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
18. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
19. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous/endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers.
Nishizawa T; Okutomi T; Inagawa H; Morikawa A; Oshima H; Soma G; Mizuno D
Mol Biother; 1991 Dec; 3(4):224-30. PubMed ID: 1768374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
